PMID- 34976976
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220104
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Electronic)
IS  - 2296-4185 (Linking)
VI  - 9
DP  - 2021
TI  - Cytotoxic Potential of Biogenic Zinc Oxide Nanoparticles Synthesized From Swertia 
      chirayita Leaf Extract on Colorectal Cancer Cells.
PG  - 788527
LID - 10.3389/fbioe.2021.788527 [doi]
LID - 788527
AB  - Chemotherapy side effects, medication resistance, and tumor metastasis impede the 
      advancement of cancer treatments, resulting in a poor prognosis for cancer 
      patients. In the last decade, nanoparticles (NPs) have emerged as a promising 
      drug delivery system. Swertia chirayita has long been used as a treatment option 
      to treat a variety of ailments. Zinc oxide nanoparticles (ZnO-NPs) were 
      synthesized from ethanolic and methanolic extract of S. chirayita leaves. ZnO-NPs 
      were characterized using UV-visible spectroscopy, Fourier transform infrared 
      spectroscopy (FTIR), scanning electron Microscopy (SEM), high-resolution 
      transmission electron microscopy (HRTEM), and X-ray diffraction (XRD). Its 
      anti-cancer activities were analyzed using cytotoxicity assays [MTT assay and 
      acridine orange (AO) staining] and quantitative real-time PCR (qRT-PCR) using 
      colorectal cancer (CRC) cells (HCT-116 and Caco-2) and control cells (HEK-293). 
      The ZnO-NPs synthesized from the ethanolic extract of S. chirayita have an 
      average size of 24.67 nm, whereas those from methanolic extract have an average 
      size of 22.95 nm with a spherical shape. MTT assay showed NPs' cytotoxic 
      potential on cancer cells (HCT-116 and Caco-2) when compared to control cells 
      (HEK-293). The IC(50) values of ethanolic and methanolic extract ZnO-NPs for 
      HCT-116, Caco-2, and HEK-293 were 34.356 +/- 2.71 and 32.856 +/- 2.99 mug/ml, 52.15 +/- 
      8.23 and 63.1 +/- 12.09 mug/ml, and 582.84 +/- 5.26 and 615.35 +/- 4.74 mug/ml, 
      respectively. Acridine orange staining confirmed the ability of ZnO-NPs to induce 
      apoptosis. qRT-PCR analysis revealed significantly enhanced expression of 
      E-cadherin whereas a reduced expression of vimentin and CDK-1. Altogether, these 
      results suggested anti-cancer properties of synthesized ZnO-NPs in CRC.
CI  - Copyright (c) 2021 Berehu, S, Khan, Chakraborty, Lavudi, Penchalaneni, Mohapatra, 
      Mishra and Patnaik.
FAU - Berehu, Hadgu Mendefro
AU  - Berehu HM
AD  - Disease Biology Laboratory, School of Biotechnology KIIT Deemed to Be University, 
      Odisha, India.
FAU - S, Anupriya
AU  - S A
AD  - Disease Biology Laboratory, School of Biotechnology KIIT Deemed to Be University, 
      Odisha, India.
FAU - Khan, Md Imran
AU  - Khan MI
AD  - Disease Biology Laboratory, School of Biotechnology KIIT Deemed to Be University, 
      Odisha, India.
FAU - Chakraborty, Rajasree
AU  - Chakraborty R
AD  - Disease Biology Laboratory, School of Biotechnology KIIT Deemed to Be University, 
      Odisha, India.
FAU - Lavudi, Kousalya
AU  - Lavudi K
AD  - Disease Biology Laboratory, School of Biotechnology KIIT Deemed to Be University, 
      Odisha, India.
FAU - Penchalaneni, Josthna
AU  - Penchalaneni J
AD  - Department of Biotechnology, Sri Padmavati Mahila Visvavidyalam, Tirupati, India.
FAU - Mohapatra, Bibhashee
AU  - Mohapatra B
AD  - Disease Biology Laboratory, School of Biotechnology KIIT Deemed to Be University, 
      Odisha, India.
FAU - Mishra, Amrita
AU  - Mishra A
AD  - Disease Biology Laboratory, School of Biotechnology KIIT Deemed to Be University, 
      Odisha, India.
FAU - Patnaik, Srinivas
AU  - Patnaik S
AD  - Disease Biology Laboratory, School of Biotechnology KIIT Deemed to Be University, 
      Odisha, India.
LA  - eng
PT  - Journal Article
DEP - 20211215
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC8714927
OTO - NOTNLM
OT  - Swertia chirayita
OT  - biogenic
OT  - colorectal cancer
OT  - cytotoxicity
OT  - zinc oxide nanoparticles
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/04 06:00
MHDA- 2022/01/04 06:01
PMCR- 2021/01/01
CRDT- 2022/01/03 05:47
PHST- 2021/10/02 00:00 [received]
PHST- 2021/11/23 00:00 [accepted]
PHST- 2022/01/03 05:47 [entrez]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/01/04 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 788527 [pii]
AID - 10.3389/fbioe.2021.788527 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2021 Dec 15;9:788527. doi: 10.3389/fbioe.2021.788527. 
      eCollection 2021.